Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Ribonucleic Acid Interference (RNAi) Technology Market Forecast: What Value Will The Market Reach By 2030?
The ribonucleic acid interference (rnai) technology market has experienced rapid expansion in recent years. It is forecast to grow from $4.43 billion in 2025 to $5.14 billion in 2026, maintaining a compound annual growth rate (CAGR) of 15.9%. This historical growth can be attributed to several factors, including advancements in molecular biology research, the initial clinical success of rnai therapeutics, the broadening of academic gene research programs, the accessibility of robust screening libraries, and the development of biotech innovation ecosystems.
The ribonucleic acid interference (rnai) technology market size is projected to experience swift expansion in the coming years. It is anticipated to reach $9.19 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.6%. This growth during the forecast period can be attributed to the increasing commercialization of RNAi-based pharmaceuticals, a rise in investments targeting rare disease therapeutics, the broadening of nanoparticle delivery technologies, expanding pharmaceutical partnerships, and greater regulatory acceptance of gene-silencing treatments. Prominent trends throughout the forecast period involve the increasing adoption of gene silencing therapies, a rising utilization of siRNA-based drug platforms, the growing integration of RNAi into precision medicine, the expansion of targeted genetic disease treatments, and optimized delivery systems.
Get A Free Sample Report With In-Depth Market Insights:
Ribonucleic Acid Interference (RNAi) Technology Market Demand Drivers Opening New Revenue Streams
The increasing demand for targeted therapeutics is anticipated to propel the ribonucleic acid interference (RNAi) technology market’s growth moving forward. Targeted therapies are treatments specifically designed to identify and inhibit molecular abnormalities in cancer or other diseases, aiming to improve treatment precision and minimize harm to healthy cells. The rising emphasis on targeted therapies is primarily driven by advancements in precision medicine, which facilitates personalized, more effective treatments based on individual genetic profiles. Ribonucleic Acid Interference (RNAi) Technology enhances the demand for targeted therapeutics by enabling precise gene silencing to treat genetic and rare diseases. It supports the development of highly specific and effective treatments, fostering innovation in personalized medicine. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, an increase from 5 approvals in 2022. Therefore, the escalating requirement for targeted therapeutics is driving the expansion of the ribonucleic acid interference (RNAi) technology market.
Ribonucleic Acid Interference (RNAi) Technology Market Segment Outlook: Which Categories Are Growing Fastest?
The ribonucleic acid interference (rnai) technology market covered in this report is segmented –
1) By Product: Micro Ribonucleic Acid (miRNA), Small Interfering Ribonucleic Acid (siRNA), Other Products
2) By Delivery Method: Viral Vectors, Nanoparticles, Chemical Modifications, Physical Methods
3) By Application: Therapeutics, Drug Discovery, Agriculture, Diagnostics
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)
Subsegments:
1) By Micro Ribonucleic Acid (miRNA): Micro Ribonucleic Acid Mimics, Micro Ribonucleic Acid Inhibitors, Micro Ribonucleic Acid Expression Vectors, Micro Ribonucleic Acid Profiling And Quantification Kits
2) By Small Interfering Ribonucleic Acid (siRNA): Small Interfering Ribonucleic Acid Synthetic Duplexes, Small Interfering Ribonucleic Acid Dicer Substrate Molecules, Small Interfering Ribonucleic Acid Self Delivering Conjugates, Small Interfering Ribonucleic Acid N Acetylgalactosamine Conjugates
3) By Other Products: Short Hairpin Ribonucleic Acid Expression Constructs, Ribonucleic Acid Interference Screening Libraries, Ribonucleic Acid Interference Transfection Reagents, Micro Ribonucleic Acid And Small Interfering Ribonucleic Acid Research Kits
Ribonucleic Acid Interference (RNAi) Technology Market Trends Powering Strategic Industry Growth
Prominent companies within the ribonucleic acid interference (RNAi) technology market are focusing on platform integration, including strategic funding and support, to optimize the development, delivery, and commercialization of RNA interference (RNAi) therapeutics. This strategy aims to foster a sustainable pipeline of numerous programs across various disease areas. Strategic funding and support involve securing investments and resources from venture capital, industry partners, and other stakeholders to accelerate the research, development, and market launch of RNA interference (RNAi) therapeutics. As an illustration, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, received $135 million in Series A financing led by ARCH Venture Partners, with additional participation from other leading life sciences investors, to advance the future of RNA interference (RNAi)-based medicine. This funding will facilitate the development of RNAi-based medicine by leveraging its proprietary lipid nanoparticle (LNP) delivery platform, which is engineered to target tissues beyond the liver with high precision. This platform is designed to overcome a key historical limitation in the field, thereby enabling the development of therapies for an expanded range of genetic disorders.
Ribonucleic Acid Interference (RNAi) Technology Market Leading Companies And Competitive Benchmarking
Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.
View The Full Ribonucleic Acid Interference (RNAi) Technology Market Report:
Ribonucleic Acid Interference (RNAi) Technology Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
